The Impact of Frequent SARS-CoV-2 Testing on Weekly Case Rates Among Long-Term Care Facilities in Florida

Competing Interest Statement

Lao-Tzu Allan-Blitz served as a consultant for Curative Inc., Belal Aboabdo served as an employee of Curative Inc., Isaac Turner is Chief Technology Officer and Co-Founder of Curative Inc., and Jeffrey D. Klausner served as an independent medical director of Curative Inc.

Funding Statement

There was no funding for this project. This research was supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Mass General Brigham Institutional Review Board exempted the study of de-identified patient data

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes